Investing.com - Shares in Eli Lilly (NYSE: LLY) sank by over 12% in premarket U.S. trading on Thursday after a study showed that the pharmaceutical giant’s weight-loss pill cut body weight by less ...

Earnings, adjusted for one-time gains and costs, came to $6.31 per share. The results surpassed Wall Street expectations. The ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists ...

Eli Lilly has hoped its candidate weight loss pill would safeguard its lead in the obesity market, but new results may prove ...

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2025. "Lilly delivered another quarter ...

Eli Lilly (LLY) stock dips as the company reports Phase 3 trial results for its oral obesity drug orforglipron. Read more ...

The experimental obesity medicine is one of two that could offer alternatives to weight-loss injections within the next year ...

Trump’s tariffs, including new levies that took effect Thursday, are affecting global markets. Follow along for live updates on the Dow, S&P 500 and Nasdaq.

As households combining three-plus generations become more common, advisors have an opportunity to address their needs.

Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...